clinical studies have visible hair growth

shown

San Diego, CA (openPR) 13 April 2010

histogenic, Inc., a company developing regenerative medicine solutions to the products of the cells were cultured under conditions embryonic born today announced this year’s data, the results of the pilot-hair complex (HSC) stimulate hospitals. Statistically significant growth of new hair was treated in patients with HSC time follow, observed one year after treatment with single HSC.

addition to the number of new hair, a statistically significant (p

display this new data that a single HSC treatment not only allows for faster hair growth (statistically significant increase in the number of terminal hairs, the density and thickness of hair shaft diameter of the hair was at three months) seen, but that these results persist over time.

“Seeing the growth of hair after this year, a follow-up is truly revolutionary,” said Dr. Craig Ziering, Ziering Medical founder and principal investigator of the study at HSC. “Not only currently available non-surgical treatments showed limited hair growth, but new hair is lost shortly after discontinuation of use. We now have the first evidence that HSC increases the number of hairs, and that the effects of treatment are sustainable.”

pilot trial of 24 subject clinical HSC is a double-blind, placebo-controlled disadvantages of the safety assessment in the clinical use of injectable product, such as hair growth. The quantitative analysis of macro and clinical biopsies in question were used to evaluate the safety and efficacy of treatment. No adverse events were observed at any point of time, including the first year of monitoring.

HSC is a proprietary formulation of naturally secreted proteins and embryonic-like growth factors. In addition to Wnt 7a as essential in the induction and maintenance of hair follicle growth recognized that includes a multitude of complex factors normally produced by embryonic cells and are important for the hair cycle, as follistatin. Although embryonic-like conditions, these materials are reinforced histogenic manufacturing unique, unwanted proteins and growth factors, including Wnt 5a, which was shown to be associated with cancer, are eliminated.


“The development of hair follicles that results from a complex interplay of factors is still riddled”

, said Dr. Jonathan Mansbridge histogenic Chief Scientific Officer. “However, essential on many factors for the growth of hair, such as Wnt 7a, follistatin, VEGF and KGF in HSC and their secretion from cells is stimulated by the culture conditions we do. The conditions under which our embryonic cells not only up-regulation of genes with produced by hair growth, but induced the production of these factors more important than those observed with other cultural conditions. “

HSC is a unique composition of the growth of embryonic cells from newborn conditions. Microgravity results hypoxia / large amounts of follistatin (41.6 ng / ml in disadvantages HSC 6.75 ng / ml in normal culture conditioned media), VEGF (9.1 ng / ml versus 2 ng / ml) 5.4, KGF ( ng / ml versus 2.1 ng / ml), and a lack of healing of TGF beta (0 ng / ml versus 1.7 ng / ml in normal cultures). This composition is covered by pending U.S. Patent # 2010/0047305.

.
be
The full results of the clinical study at HSC Society for Investigative Dermatology (SID) presented annual meeting in Atlanta will be held, 5-8 May 2010. Abstracts of work has been published by SID now http://sid.abstractcentral.com/login for review.

histogenic is currently in development for the next clinical study of the HSC, to begin the end of 2010. The next attempt to further examine the safety and effectiveness as a HSC injection for hair growth and evaluate optimal dosage and treatment delivery. Histogenic currently seeking a Series B investment, its finance with which the next stages of development and testing of HSC.


About

histogenic

histogenic, in 2007 launched, aims to regenerative medicine by developing a series of high-quality products that do not define embryonic stem cells or animal components to include new. Through proprietary bioreactors that mimic the environment histogenic embryonic cells newborns will be asked to produce naturally from the vital proteins and growth factors that the Company has developed its rich product portfolio. Histogenic has two product families – a unique complex of protein and liquid embryonic-like growth factors and human extracellular matrix (ECM) material ExCeltrix. For more information, please visit http://www.histogen.com.


>

clear = “all”
Boost treatment